Intas Medi Devices Limited - Due diligence report

A 360° intelligence report on Intas Pharmaceuticals: trust score, financial health, credit view, compliance, directors, growth and distress …

2010-07-07 Ahmedabad, Gujarat Strike Off Unlisted
Share
Connect MCP
IM Intas Medi Devices Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Intas Pharmaceuticals — 360° Intelligence Report

Generated from MCA filings & public records
56/100
Trust Score
Moderate

Intas Pharmaceuticals is assessed as Moderate with a Trust Score of 56/100. Intas Pharmaceuticals is a public limited indian non-government company incorporated in 2010, operating in the Chemicals sector. Processed financial statements are not yet available for trend analysis. Based on MCA filings and public records, it currently shows a high compliance risk and moderate financial risk profile.

Report generated on 10 Aug 2026 from the latest processed filings. Intas Medi Devices Limited snapshot & full profile →

Financial Health › Neutral
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Caution

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
56/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
23/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
50/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreNo Data
N/A
Needs at least two filed years to measure growth.
Distress ScoreModerate
55/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 1 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 50/100 Moderate
  • Negative operating earnings - debt service depends on external support.
  • No open charges - unencumbered balance sheet.
  • Working-capital cover adequate.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 23/100 Caution Indicated
  • Company status is "Strike Off" - not Active.
  • Last balance sheet is for Mar 2017 - filings overdue.
  • Litigation present in 1 court forum(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
URMISH HASMUKH CHUDGAR 01234567 Director 01/04/2018 6 yrs Approved
HASMUKH CHUDGAR 01234567 Director 01/04/2018 6 yrs Approved
BINISH HASMUKH CHUDGAR 01234567 Director 01/04/2018 6 yrs Approved
NIMISH HASMUKH BHAI CHUDGAR 01234567 Director 01/04/2018 6 yrs Approved
  • 4 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2017 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Intas Pharmaceuticals Limited
Subsidiaries
-
Group entities
-
Capital events
2 allotment(s) · 1 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Intas Pharmaceuticals Limited Holding Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth N/A · Distress 55
Growth signals & trust indicators
Operating for 16+ years.
Active EPFO - real payroll on record.
Distress signals & risk flags
Statutory filings appear overdue.
Adverse company status: Strike Off.
Compliance score is weak (23/100).
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence42/100
Caution indicated
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment43/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance gaps should be priced into terms.
Investor view32/100
Limited indicators at present
Growth quality and scalability through an investor lens.
  • No clear growth signals in the filed years.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 12 events
29 Sep 2017
Last AGM held
Annual general meeting
05 Sep 2017
Director ceased
BINISH HASMUKH CHUDGAR
31 Mar 2017
Latest balance sheet
Filed with ROC
31 Mar 2016
Share transfer (FY 2016)
2695000.00000000 shares to ANDRE LABORATORIES LIMITED
12 Jun 2015
Director ceased
DRIGESH PRAMODBHAI MITTAL
30 Mar 2012
Securities allotted
1000000.00 Equity Shares - 6.00 cr raised
31 Mar 2011
Securities allotted
4450000.00 Equity Shares - 4.45 cr raised
07 Jul 2010
Incorporated
Registered with Roc Ahmedabad
Director appointed
URMISH HASMUKH CHUDGAR (Director)
Director appointed
HASMUKH CHUDGAR (Director)
Director appointed
BINISH HASMUKH CHUDGAR (Director)
Director appointed
NIMISH HASMUKH BHAI CHUDGAR (Director)
10

Key Observations

Auto-generated from the data above
4 active director(s) / partner(s); board looks stable and experienced.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2017 annual return.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Target Chemicals Pvt Ltd U74899DL1990PTC040254 New Delhi, Delhi, India
Sampoorti Agrocare Private Limited U24100DL2014PTC267469 New Delhi, Delhi, India
Cybele Herbal Laboratories Private Limited U85199KL1997PTC011963 Ernakulam, Kerala, India
Astrom Bioscience Private Limited U51397DL2012PTC231902 New Delhi, Delhi, India
Competent Chemicals International Private Limited U24232AP2013PTC089879 Visakhapatnam, Andhra Pradesh, India
Manlike Chemical And Pharmaceutical Company Private Limited U24232DL2010PTC210523 Delhi, Delhi, India
Ariha Chemicals Private Limited U24301MH2013PTC245730 Navi Mumbai, Maharashtra, India
Ganraj Enterprises Limited U51909PN2004PTC020050 Pune, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Intas Pharmaceuticals before audits and certifications: compliance score 23/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Intas Pharmaceuticals: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Enhanced diligence advised. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Limited indicators at present. Growth score n/a, margin trends, ownership structure and peer set for Intas Pharmaceuticals - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Caution indicated. Trust score 56/100, distress signals and MSME payment-delay disclosures - know whether Intas Pharmaceuticals pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Intas Pharmaceuticals - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Intas Pharmaceuticals an active company?

Intas Pharmaceuticals has MCA status “Strike Off” with a compliance score of 23/100 (Caution Indicated).

Is Intas Pharmaceuticals financially healthy?

Intas Pharmaceuticals has a Financial Health Score of 50/100 (Moderate) based on its filed financial statements.

Should I do business with Intas Pharmaceuticals?

Its overall Trust Score is 56/100 (Moderate). Vendor verdict: Caution indicated. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Intas Pharmaceuticals?

The ultimate holding entity is Intas Pharmaceuticals Limited. 4 active director(s) are on record.

Does Intas Pharmaceuticals have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Intas Pharmaceuticals up to date with its ROC filings?

Last balance sheet is for Mar 2017 - filings overdue. Overall compliance score: 23/100 (Caution Indicated).

Is it risky to lend to Intas Pharmaceuticals?

Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Enhanced diligence advised.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.